Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 347 participants.

Also called NCT01113047

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 347 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01113047
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01113047. Non-randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2010-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
Acronym
AWESOME
Condition
Essential Hypertension
Intervention (Drug)
Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
Lead sponsor
Novartis (class: industry)

Record details

Record id
cardio:ct-nct01113047
Content hash
8f6fb6c66ae0b5dc6923e0cf374498274ab6234513c331025ed55d1b9cc5b44d